Missed the PREFER framework webinar? Recording now available


Incorporating patient preferences into decision-making is an important part of patient-focused drug development. The lack of a clear, practical framework for measuring patient preferences was one of stakeholders' main concerns brought up during PREFER’s initial research. On 31 August, we introduced the PREFER framework for patient preference studies, with a particular focus on points to consider for method selection and the application of preference study results to inform regulatory and HTA decision-making. The webinar was recorded, and you can now watch it in full, or the parts that interest you the most.

The recoded webinar is now available on the PREFER YouTube channel. You can watch it in its entirety or scroll to find the parts below. If you want to be invited to future PREFER webinars, sign up for our newsletter! Or have a look at our event calendar to find out what has been planned already.

Introduction to the PREFER framework & what we’d like this to achieve

Conny Berlin, IMI PREFER Project Leader & Global Head, Quantitative Safety and Epidemiology Novartis Pharma AG, Switzerland

How the PREFER framework addresses the study purpose; study organization, design & conduct

Kristin Bullok, Benefit-Risk Management Scientist, Global Patient Safety; Eli Lilly and Company, United States

Points to consider for method selection

Brett Hauber, Senior Director, Patient Preference Elicitation Pfizer, United States

PREFER framework continued: application of preference data to inform regulatory decision-making

Bennett Levitan, Senior Director, Benefit-Risk Assessment, Global R&D Epidemiology; Janssen Research & Development, United States

PREFER framework continued further: application of preference data to inform HTA decision-making

Irina Cleemput, Scientific Programme Director Belgian Health Care Knowledge Centre (KCE), Belgium

Last modified: 2021-11-10